Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
Go back to Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026| Enliven Marketing Technologies Corporation (NASDAQ: ENLV) | Delayed: 0.61 -0.01 (1.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.62 | 52 Week High | $0.94 | |||
| Open | $0.60 | 52 Week Low | $0.47 | |||
| Day High | $0.63 | P/E | N/A | |||
| Day Low | $0.59 | EPS | $-0.11 | |||
| Volume | 268,084 | |||||
